Gain Therapeutics Reports Topline Data from P-I Study of GT-02287 to Treat Parkinson’s Disease
Shots:
- The P-I study assessed safety, tolerability & PK of GT-02287 among healthy subjects (n=72; 64yrs.). Its P-Ib trial in patients is anticipated in Q4’24
- Data verified GT-02287’s presence in cerebrospinal fluid with effective target engagement plus, it was safe & well-tolerated at all dose levels across age groups (15% were over 50yrs. of age). Favorable safety profile, therapeutic plasma levels & CNS exposure suggest its potential as a treatment of Parkinson’s disease with/without GBA1 mutation
- GT-02287 (oral) is a brain-penetrant small molecule that re-establishes the function of glucocerebrosidase (GCase) enzyme, which is impaired by GBA1 mutations or age-related stress
Ref: Gain Therapeutics | Image: Gain Therapeutics
Related News:- Bayer and Evotec Join Forces to Develop Treatment for Cardiovascular Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
